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The leading risk factor for Clostridioides (Clostridium) difficile infection (CDI) is broad-spectrum antibiotics, which lead to low 
microbial diversity, or dysbiosis. Current therapeutic strategies for CDI are insufficient, as they do not address the key role of the 
microbiome in preventing C. difficile spore germination into toxin-producing vegetative bacteria, which leads to symptomatic dis-
ease. Fecal microbiota transplant (FMT) appears to reduce the risk of recurrent CDI through microbiome restoration. However, a 
wide range of efficacy rates have been reported, and few placebo-controlled trials have been conducted, limiting our understanding 
of FMT efficacy and safety. We discuss the current knowledge gaps driven by questions around the quality and consistency of clin-
ical trial results, patient selection, diagnostic methodologies, use of suppressive antibiotic therapy, and methods for adverse event 
reporting. We provide specific recommendations for future trial designs of FMT to provide improved quality of the clinical evidence 
to better inform treatment guidelines.
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In this review, we address the current understanding of FMT ef-
ficacy and safety to stimulate critical thinking about the gaps in 
clinical evidence needed to better inform Clostridioides difficile 
infection (CDI) treatment. This discussion also readily applies 
to investigational microbiome drugs, as we seek to improve 
therapeutic options for patients to mitigate risk.
Why Do Antibiotics Often Fail in CDI Treatment?
Exposure to broad-spectrum antibiotics is the main risk factor 
for primary CDI, the leading cause of nosocomial diarrhea [1]. 
CDI recurrence is common, with rates of up to 40%–60% among 
those with a history of ≥2 episodes [2]. Recurrences follow treat-
ment discontinuation within 8 weeks, although the majority 
occur within 1–3 weeks, highlighting the paradox of treating an 
antibiotic-associated infection with more antibiotics [3].
High rates of treatment failure can only be fully understood 
within the context of the pathogen’s life cycle and the role of the 
healthy microbiome in reducing recurrence [4–6]. C. difficile has 
a 2-phase life cycle with dormant spores germinating into toxin-
producing vegetative bacteria, which leads to colitis [7]. Although 
the factors that initiate germination are incompletely understood, 
bile acids play an important role [6]. Primary bile acids, which 
are synthesized in the liver and secreted into the gastrointestinal 
tract, set up favorable conditions for germination. By contrast, 
secondary bile acids, the metabolic product of key commensal 
bacteria, inhibit vegetative bacterial growth [5]. These and other 
key microbe-derived metabolites are reduced when antibiotics 
kill innocent bystander bacteria, which are critical to these meta-
bolic processes. For example, a relative increase of primary to sec-
ondary bile acid concentrations facilitates spore germination and 
vegetative outgrowth, leading to recurrence. Furthermore, CDI-
targeted antibiotics maintain and exacerbate this low-diversity 
microbiome (ie, dysbiosis) [8]. Thus, antibiotics are a main driver 
of compositional and functional microbiome changes and are in-
sufficient as a sole therapeutic strategy, as microbiome recovery is 
essential for durable clinical resolution. Other potential mechan-
isms that inhibit C. difficile include niche exclusion, competition 
for nutrients, and bacteriocins [6].
Recurrent CDI Requires a 2-Pronged Treatment Approach
These foundational principles suggest the need for a 2-pronged 
therapeutic approach. However, there are currently no approved 
microbiome therapeutics, although several investigational 
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agents are in clinical trials [9, 10]. A burgeoning literature has 
emerged on fecal microbiota transplant (FMT), the transfer of 
minimally processed stool from a donor to a recipient. Clinical 
resolution is associated with increased microbial diversity and 
secondary bile acids, providing proof of concept of the critical 
role of microbiome restoration [11–13].
The Infectious Diseases Society of America/Society for 
Healthcare Epidemiology of America (IDSA/SHEA) guidelines 
recently recommended FMT for multiply recurrent CDI, de-
spite “moderate quality” evidence, reflecting the great unmet 
need [14]. Why are the data only ranked as “moderate quality” 
evidence? The IDSA/SHEA guidance suggests that FMT re-
sponse rates may be influenced by patient selection, proximity 
of the last CDI episode, and clinical trial design. Herein, we de-
scribe the methodologic flaws that limit estimates of FMT effi-
cacy and safety for recurrent CDI:
• Quality of study designs evaluating FMT efficacy
• Selection of appropriate diagnostic assays for CDI
• Importance of a placebo arm when evaluating any investiga-
tional agent, particularly in a disease without any pathogno-
monic symptoms or signs
• Use of prolonged suppressive antibiotic regimens before 
FMT
• Appropriate comparator treatments
In addition, we address concerns about emerging infections, 
such as SARS-CoV-2 and transmission of undetected pathogens 
[15, 16]. Finally, we propose recommendations for future FMT 
study designs, also applicable to investigational microbiome 
drugs, to improve the quality of the clinical evidence needed for 
well-supported treatment guidelines.
What Is the Quality of Data Supporting FMT Efficacy in Reducing Risk of 
CDI Recurrence?
Although FMT appears to reduce risk of CDI recurrence, ac-
curate estimates of efficacy and safety are limited by the design 
of published trials [17]. Case series or individual case reports 
have supported efficacy estimates up to 93%, but small un-
controlled trials are prone to bias [18]. Notably, a 2019 meta-
analysis found that FMT was associated with lower cure rates 
in randomized trials (67.7%) compared with open-label studies 
(82.7%; P < .001) [19].
A 2017 systematic review highlighted that 87% of FMT 
reports were nonrandomized trials missing details on key 
methodology, including (a) donor eligibility criteria, (b) stool 
processing methods, (c) dosage, dosing frequency, route, and 
types of stool used (eg, fresh or frozen), and (d) methods of 
preparing the FMT recipient (eg, antibiotics, lavage) [20]. The 
authors concluded that incomplete reporting “raises multiple 
problems for patients, clinical researchers and health regu-
lators.” The authors of another meta-analysis described the 
evidence as “low-strength,” limiting firm conclusions regarding 
efficacy rates [21].
Selecting the Appropriate C. difficile Diagnostic Assay
Chronic diarrhea is a common complaint in the outpatient 
clinic attributable to a multitude of noninfectious pathophysio-
logic etiologies, including osmotic, secretory, and inflammatory 
mechanisms and altered physiology [22]. Diarrhea is also the 
chief symptom of CDI, often in isolation of any other clinical 
finding, underscoring the importance of a rigorous diagnostic 
test with high specificity and positive predictive value [23].
In primary CDI, proponents of nucleic acid amplification 
testing (NAAT) affirm its high sensitivity, whereas detractors 
highlight its inability to distinguish colonization from infec-
tion [24]. Supporters of assays for toxin production highlight its 
greater specificity and positive predictive value compared with 
NAAT for this toxin-mediated infection, while detractors cite 
risk of false-negative results. However, studies that have correl-
ated testing with clinical outcomes have supported higher pre-
dictive values for toxin testing compared with NAAT for true 
CDI; thus, NAAT use can lead to overdiagnosis [23]. However, in 
clinical practice, toxin testing may not always be readily available 
and may not have optimal sensitivity, and so the “art of medicine” 
and clinical judgment must guide clinical decision-making.
In recurrent CDI, overdiagnosis with NAAT is of even greater 
concern. In fact, the recent CDI guidelines made a firm case for 
always using toxin testing for suspected recurrent infection in 
clinical practice [14]. Why is toxin testing so critical in this clin-
ical scenario? After treatment, NAAT will likely be positive due 
to spore persistence, whether or not the patient’s symptoms are 
related to C. difficile. In 1 epidemiologic study of patients with 
CDI resolution, fecal shedding of spores was detected in 56% of 
patients 1–4 weeks after treatment discontinuation [25]. Up to 
25% of CDI patients can develop postinfectious irritable bowel 
syndrome (IBS), which can be misdiagnosed as active infection 
if only NAAT is utilized [26].
Although these caveats are important to patient management, 
they have even greater implications for clinical trial design and 
subject selection. In the context of a clinical trial, it is essential 
that all study candidates have the disease of interest and that 
toxin testing has the best predictive value for true infection. 
If there is uncertainty about this fundamental point, then the 
study is essentially flawed; analyses of efficacy (and safety) will 
be inaccurate, leading to under- or overestimates of effect. In 
contrast, in diseases with clear-cut surrogate markers, like HIV 
RNA and CD4 cell counts, enrollment criteria and end points 
are straight-forward and objective. But in recurrent CDI, toxin 
testing is a critical element for trial design, particularly in light 
of the prolonged carrier state [25]. Toxin testing ensures (a) en-
rollment of subjects with true disease and (b) confirmation that 
symptomatic recurrence is due to CDI rather than an alternate 
cause of diarrhea (eg, postinfectious IBS) [26].
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Despite the concerns raised above, as the pendulum has 
swayed in clinical practice toward NAAT, so have clin-
ical studies. Trials performed before NAAT availability (eg, 
fidaxomicin) relied exclusively on toxin testing [27]. More re-
cent trials have allowed detection of either toxin production 
(enzyme immunoassay) or toxin genes (polymerase chain re-
action) according to investigator discretion, which may have 
led to inappropriate subject selection [28]. Crucially, to date, no 
randomized, placebo-controlled FMT trials for recurrent CDI 
have required toxin testing as a criterion for patient selection. 
The veracity of the CDI diagnosis in subjects recruited to these 
relatively more robust trials remains uncertain.
What Insights Does a Placebo Arm Provide in Clinical Trials of 
Recurrent CDI?
A critical issue in assessing the quality of evidence supporting 
FMT is the relative lack of high-quality placebo-controlled 
trials [21]. A placebo arm provides valuable information about 
the study population that cannot reliably be determined in 
any other way. For example, if there are low event rates among 
subjects in the placebo arm, then the efficacy of the treatment 
intervention is no longer evident, as most subjects are at low 
risk for the outcome of interest [29].
This concept is well illustrated by a National Institutes of 
Health (NIH)–funded FMT trial that compared donor FMT 
with autologous FMT to determine their relative therapeutic ef-
ficacy [30]. At 1 of the 2 study sites, rates of clinical resolution 
were 90% in both the intervention and placebo arms, raising 
concerns that some subjects did not have true recurrent CDI 
on study entry. Indeed, the authors acknowledged that many of 
study participants may have had simple colonization rather than 
true CDI, due to the use of NAAT for study eligibility. These 
observations support the importance of a placebo compar-
ator (and toxin-based testing), particularly when interpreting 
studies suggesting high FMT efficacy rates [31].
What Are the Implications of Using Suppressive Antibiotics Before FMT?
In many trials, FMT is offered to subjects with a “history of recur-
rence,” which may have occurred long before study entry. Many of 
these study participants are continued on prolonged suppressive 
antibiotics, such as vancomycin, to “control” their CDI, which 
confounds the evaluation of FMT and the true performance of 
a placebo arm. In the NIH-funded trial mentioned above, some 
patients were on long-term suppressive antibiotics for up to 148 
weeks before study entry [30]. This is a critical issue, as 1 retro-
spective study identified the absence of a vancomycin taper be-
fore FMT as the leading risk factor for CDI recurrence [32].
The practice of allowing suppressive antibiotics before entry 
into an FMT trial raises a key question: Was the subject at risk 
for recurrence? A  Canadian study by Hota and colleagues 
is very informative in this regard. In this uniquely designed 
trial, subjects with a history of multiply recurrent CDI were 
randomized to FMT or a vancomycin taper, only after they 
presented with another clinical recurrence [33]. Remarkably, 
58% of the screened subjects never had a subsequent recur-
rence, so they were not randomized. CDI experts have hailed 
this trial as arguably the most rigorous in the field to examine 
the efficacy of a therapeutic intervention for acute CDI [34, 35]. 
This study design assesses the true efficacy of FMT to prevent 
CDI recurrence, because patients are treated during the acute 
phase immediately after recurrence rather than following a dis-
tant episode, where the risk of contemporaneous recurrence is 
unknown.
What Is the Efficacy of FMT vs a Vancomycin Taper?
Although the IDSA/SHEA guidelines recommend a vanco-
mycin pulse/taper for treatment of recurrent CDI, there are few 
data examining the efficacy of such regimens or their efficacy 
compared with FMT. The Canadian study noted above is the 
only trial that directly compared 2 weeks of vancomycin fol-
lowed by either FMT or a vancomycin pulse/taper given over 
an additional 4 weeks [33]. The working hypothesis was that 
FMT would be superior to vancomycin taper. However, after 
randomization of 28 subjects, the study was stopped early for 
futility when an interim analysis showed comparative efficacy 
of 44% for FMT vs 58% for vancomycin.
The only other trial that compared FMT with vancomycin 
used a 2-week antibiotic course, shorter than the recommended 
6-week course [11, 14]. Thus, the comparator antibiotic arm 
was suboptimal, as reflected by a clinical resolution rate of 31%.
What Is the Impact of an Open-Label Trial on Estimates of Efficacy?
A major challenge to placebo-controlled trials is the wide avail-
ability of FMT. Stool banks distribute FMT under “enforcement 
discretion,” which permits use of this investigational agent 
without an IND for recurrent CDI treatment, as long as patients 
give informed consent [36]. The public perception of FMT as 
a highly effective and safe product represents a challenge for 
enrolling subjects in placebo-controlled investigational drug 
trials.
To attract study participants, some company sponsors have 
adopted a strategy of offering active drug to all nonresponders 
through an open-label trial, following participation in a 
placebo-controlled trial. However, the availability of an open-
label trial may negatively impact the primary trial if patients 
seek active drug before meeting protocol-defined criteria. An 
example of this phenomenon was observed in a double-blind, 
placebo-controlled trial of RBX2660, a stool-derived micro-
biota suspension [10]. In this phase 2b study, 4 criteria were re-
quired to meet the definition of treatment failure (ie, recurrence 
of diarrhea, a positive C. difficile test, need for retreatment as 
determined by the investigator, and no alternative cause iden-
tified for symptom recurrence). Several subjects were deemed 
a “treatment failure” and rolled over into the open-label trial, 
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despite not fulfilling the recurrence criteria. In fact, some 
subjects had negative C. difficile test results. These subjects were 
strictly counted as treatment failures in this controlled trial, 
which may have led to an underestimate of efficacy.
Notably, the blinded and open-label arms of this RBX2660 
study had remarkably different efficacy estimates; in the open-
label study, clinical resolution was achieved in 88%, whereas in 
the main placebo-controlled study clinical resolution rates were 
lower, at 61%–67% [10]. The 88% RBX2660 efficacy rates are 
consistent with those observed in open-label FMT trials. These 
observations reinforce the importance of a placebo-controlled 
trial as the preferred high-quality standard, particularly in a dis-
ease without any pathognomonic signs or symptoms or a defini-
tive “gold standard” diagnostic test.
What Are the Gaps in Understanding FMT Safety Risk?
Many experts state that FMT is “safe” based on a multitude of 
uncontrolled trials without a placebo control. Closer examina-
tion of adverse event (AE) reporting, however, suggests a need 
for caution on several grounds.
Absence of Adverse Event Reporting in Published Studies
In 1 systematic review of AEs following FMT, the authors cited 
concerns about potential underreporting, as many studies did 
not report any AEs at all [37].
Open-Label Trials
In the largest FMT trial to date, 219 subjects (mean age, 73 years) 
were randomized to fresh or frozen FMT via enema [38]. Six deaths 
(5.6%) occurred in the frozen FMT arm, and 11 deaths (11.7%) 
occurred in the fresh FMT arm; none were attributed by the in-
vestigators to FMT. Although we agree with the authors that CDI 
morbidity and mortality rates have been reported to be as high as 
15%, it is difficult to know which AEs may be treatment-related 
without the benefit of a placebo-controlled arm [39].
A few FMT proponents have argued that some patient sub-
groups, such as immunocompromised hosts, often do not 
qualify for placebo-controlled trials and need open access to 
FMT [40]. However, implicit in this statement is the implication 
that FMT has been shown to be efficacious and safe in this pa-
tient population when there are no controlled trials to support 
such assumptions.
Prospective Reporting vs Retrospective Reporting of Adverse Events
It is instructive to compare AE rates between 2 FMT products, 
which used different methods of monitoring and reporting. 
In a double-blind, placebo-controlled trial of a stool-derived 
microbiome drug product, RBX2660, 64% of subjects reported 
an AE; the distribution of these AEs was comparable by treat-
ment arm (2 doses of placebo vs 2 doses RBX2660 vs 1 dose 
RBX2660/placebo) [10] In contrast, 1 stool bank (OpenBiome, 
Cambridge, MA, USA) reported 42 AEs in 2050 subjects who 
received FMT, for an event rate of 2%; furthermore, none of the 
AEs was judged to be “definitely related to FMT” [41].
It is difficult to attribute the dramatic differences in event 
rates to major differences in the products themselves, as both 
are stool-derived. The main differences appear to be the meth-
odologies used in AE collection and reporting. In the placebo-
controlled phase 2b trial of RBX2660, AEs were systematically 
collected on a prospective basis and investigators were man-
dated to assign causality [10]. In contrast, OpenBiome asks 
clinicians to retrospectively report, and the stool bank charac-
terizes the relationship of the product to AEs rather than the 
clinicians [42, 43]. This type of methodology is prone to bias. 
Retrospective reporting may also miss connections between in-
fections and FMT if the patient is evaluated by a different health 
care provider who does not recognize the temporal relationship.
Clinical trials can facilitate connections between FMT and 
AEs. In June 2019, the Food and Drug Administration (FDA) 
reported 2 cases of invasive infections with extended-spectrum 
beta-lactamase-producing (ESBL) Escherichia coli following 
FMT linked to a single donor; both patients were immunocom-
promised, and 1 died [44]. Notably, these 2 serious events were 
identified during a clinical trial with prospective AE reporting 
to the FDA [45]. A  rigorous lookback investigation using ge-
nomic sequencing linked donor stool to both infections and 
colonization of 5 other asymptomatic recipients. Notably, these 
2 serious events, and the more subtle colonization cases, were 
identified during prospective AE reporting.
In contrast, retrospective reporting can miss FMT-related 
events. In March 2020, the FDA issued another safety alert re-
garding 2 patients infected with enteropathogenic Escherichia 
coli (EPEC) and 4 others infected with Shiga toxin–producing 
E.  coli (STEC) following FMT provided under Enforcement 
Discretion [16]. Four patients required hospitalization. All 
cases were linked to contaminated stool, with a single donor 
linked to all 4 STEC cases. Another patient died after receiving 
stool from the STEC-positive donor, although it is unknown if 
FMT contributed to this person’s death as his/her stool was not 
tested. Recall of this STEC-positive donor did not occur until a 
second case was reported [46]. The stool bank employed a rela-
tively low-sensitivity test (ie, toxin immunoassay) rather than a 
more sensitive molecular assay (ie, PCR), which may have en-
abled these transmissions [47].
Serious transmission events prompt changes in screening 
algorithms [46]. However, even mandatory guidelines 
cannot address the issue of emerging infections, including 
SARS-CoV-2, which is shed in stool for days after clinical 
resolution of symptoms [48–50]. In response to these new 
data, the FDA has issued an alert warning for providers and 
patients of potential transmission via FMT [15]. The rapid 
emergence of the COVID-19 health care crisis reminds us 
that donor screening is an imperfect science, particularly if 
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new infections are unanticipated and only recognized after 
transmission to the host [51, 52].
Serial FMT Interventions With Invasive Procedures
One trial reported 90% efficacy in 20 subjects treated with FMT, 
although deeper examination of the paper shows that first-dose 
efficacy was only 65% [53]. To reach 90% efficacy, multiple in-
fusions (2–4 per patient) were administered. Repeat infusions 
through invasive means, such as colonoscopy, should also be 
weighed in the risk/benefit analysis of any procedure, and first-
dose efficacy rates should be clearly reported.
Recommendations for Future Clinical Trials
In patients with recurrent CDI, FMT is an effective interroga-
tive tool that provides proof of concept that modulation of the 
gut microbiome is a promising avenue for drug development 
and fulfills an unmet need. However, we caution that estimates 
of efficacy remain unclear and clinical expectations of phys-
icians and patients may be exceeding the quality of the evidence 
[20, 21].
The safety of any investigational product is best understood in 
the context of a placebo-controlled trial in a sufficient number 
of patients with an adequate period of prospective follow-up. 
A national FMT registry, supported by a grant to the American 
Gastroenterology Association from the National Institutes of 
Health, has been initiated in recognition of our limited knowl-
edge of the long-term risks of FMT. The results of this study will 
not be available for many years to come. A key reason for cau-
tion regarding potential long-term consequences of FMT is the 
ever-increasing list of diseases associated with the microbiome 
[54]. Thus, manipulation of the gut microbiome, particularly 
with wholesale replacement via FMT, could have varied and 
unforeseeable consequences that are only identifiable after the 
fact [51].
Physicians should be aware of data limitations when coun-
seling patients regarding any investigational therapy. We make 
the following recommendations for future FMT trials and for 
reporting of data in publications to improve our fundamental 
knowledge of FMT safety and efficacy:
• Trials should exclusively employ toxin testing to ensure selec-
tion of subjects with true recurrent CDI [14].
• Treatment trials should enroll subjects with acute-onset CDI.
• Long-term suppressive antibiotics for CDI should be con-
sidered a key exclusion criterion.
• The number of treatments required to achieve clinical reso-
lution should be reported, as repeated FMT treatments carry 
procedural risks, depending on route of administration.
• Statistical analyses should take into account loss to follow-up 
and other AEs that lead to treatment discontinuation, which 
are considered treatment failures in most clinical trials.
• Large double-blind, placebo-controlled trials are needed for 
adequate assessment of the efficacy and safety of any inves-
tigational intervention, including FMT. Alternatively, future 
comparator trials with vancomycin pulse-taper regimens 
should be considered to fully assess if FMT offers additional 
advantages over other recommended therapeutic approaches 
[14].
CONCLUSIONS
High-quality trials are needed to improve our understanding 
of FMT efficacy and safety in order to better inform patients 
of potential benefit and, more importantly, potential risk. Only 
a few decades ago, we learned painful lessons regarding the 
purported safety of plasma-derived factors for hemophiliacs, 
which unknowingly transmitted HIV [52]. The HIV epidemic 
was well underway for approximately a decade before it was 
clinically recognized and identified. Patients deserve risk mit-
igation, which can be accomplished with thorough vetting and 
regulation. Mandatory screening guidelines for stool donors 
are urgently needed, although screening cannot prevent unan-
ticipated emerging infections. Finally, the development of in-
vestigational microbiome therapeutics with defined microbial 
consortia will offer greater confidence in drug purity, identity, 
and potency, in addition to risk mitigation for improved patient 
safety [4, 55].
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